NASDAQ$SERA
Sera Prognostics Inc-A · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Sera Prognostics' financial results for Q2 2022 were announced, highlighting a revenue increase compared to the same period last year and ongoing efforts to expand the adoption of the PreTRM® Test.
Sera Prognostics reported a revenue of $78,000 for the second quarter of 2022, compared to $20,000 for the same period in 2021. The company's net loss for the quarter was $11.5 million, and they had approximately $121 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2022.
- Revenue increased to $78,000 in Q2 2022 from $20,000 in Q2 2021.
- Operating expenses rose to $11.8 million, compared to $7.4 million in the same quarter last year.
- Net loss for the quarter was $11.5 million, up from $6.3 million year-over-year.
- The company had approximately $121 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2022.
Headline financials
Revenue & EPS history
Sera Prognostics · Revenue · Quarterly
$78K
Forward guidance
The company anticipates additional clinical and health economic publications that further illustrate the clinical utility and benefit of PreTRM® technology, supporting the achievement of their vision to improve the well-being of mothers and newborns and decreasing healthcare costs. The Company extending its operations into 2026 without the need for additional financing.
Tailwinds
- Healthcare systems aligning on incorporating PreTRM testing as an add-on to comprehensive services provided to pregnant women.
- Expanded adoption of the PreTRM® Test
- Demonstrable progress in contracting with self-insured employers
- Additional clinical and health economic publications that further illustrate the clinical utility and benefit of PreTRM® technology
- The Company extending its operations into 2026 without the need for additional financing
Headwinds
- Net losses
- Cash generation
- The potential need to raise more capital
- Revenues from the PreTRM test representing substantially all Company revenues to date
- The need for broad scientific and market acceptance of the PreTRM test
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-1.9%
Avg return
Earnings day
-3.5%
Avg return
5 days after
-3.3%
Avg return
30 days after
36%
8 / 22 earnings
Positive
+14.3%
Q3 2022
Best reaction
-11.7%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.7% | -8.0% | +18.1% | |
| Q4 2025 | -7.7% | +6.3% | +20.4% | |
| Q3 2025 | +1.7% | +8.5% | +19.0% | |
| Q1 2025 | -11.7% | -2.1% | -35.4% | |
| Q4 2024 | -5.1% | -2.2% | -17.9% | |
| Q3 2024 | -0.3% | -2.7% | -3.9% | |
| Q2 2024 | +0.0% | -1.2% | -2.2% | |
| Q1 2024 | +3.3% | -4.0% | -13.6% | |
| Q4 2023 | +3.4% | +1.1% | +7.7% | |
| Q3 2023 | -3.2% | -6.4% | +130.9% | |
| Q2 2023 | +0.8% | -10.1% | -39.9% | |
| Q1 2023 | -0.8% | -2.8% | -13.0% | |
| Q4 2022 | -10.0% | -9.5% | -22.3% | |
| Q3 2022 | +14.3% | +11.1% | -4.0% | |
| Q2 2022 | -4.1% | -6.3% | -27.3% | |
| Q1 2022 | -7.6% | -17.1% | -32.7% | |
| Q4 2021 | +3.6% | +0.3% | -39.3% | |
| Q3 2021 | +0.3% | -0.8% | -8.2% | |
| Q3 2020 | +0.3% | -0.8% | -8.2% | |
| Q2 2021 | -4.8% | -9.9% | +0.0% | |
| Q1 2021 | -4.8% | -9.9% | +0.0% | |
| Q4 2020 | -4.8% | -9.9% | +0.0% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro